The International Antiviral Society -USA has announced a 2.5-day conference on phages. Approximately 500 US and international attendees will be attending this conference. Being held from October 12 to 14, 2025, in Washington, DC, the conference will include talks, symposia, and workshops, abstract-driven presentations focused on recent scientific advances and future clinical applications of phages.
Discussions will include current phage susceptibility testing, methods, validation for clinical use, and the potential of molecular approaches to testing. Clinical trials designs for phage therapy targeting antimicrobial-resistant and mycobacterial infections, with attention to regulatory considerations for treatment approval, will also be discussed.
Other discussions will include phages in preclinical models and evaluating the safety and efficacy of phage therapy before clinical trials. Phage diversity, current challenges in the treatment of biofilm-associated infections, various innovative delivery methods, examining phage virulence and host resistance, assembly of synthetic phage genomes, and the integration of AI and machine learning for predictive phage therapy will all be part of these discussions.
The conference is open for abstract submissions from across the globe.
Check here
